{"schema_version":"secwatch.filing_event.v1","accession":"0001828185-25-000018","form_type":"8-K","ticker":"BRNS","cik":"0001828185","company_name":"Barinthus Biotherapeutics plc.","filed_at":"2025-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.121262+00:00","generated_at":"2026-05-24T10:44:02.316491+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Barinthus Bio FY2024 net loss $61.1M; cash runway into 2027; VTP-1000 data Q3 2025","bullets":["Net loss of $61.1M ($1.55 per share) vs $73.3M in 2023; goodwill impairment of $12.2M.","Cash $112.4M at Dec 31, 2024, down from $142.1M; expected cash runway into 2027.","Revenue $15.0M from Vaxzevria royalties (no future payments expected).","Lead candidate VTP-1000 (celiac disease) Phase 1 AVALON trial; single ascending dose data expected Q3 2025.","VTP-300 for CHB achieved 8 participants with HBsAg loss, 2 functional cures; Phase 2b data due Q2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001828185-25-000018","json":"https://secwatch.observer/filing/0001828185-25-000018.json","markdown":"https://secwatch.observer/filing/0001828185-25-000018.md","text":"https://secwatch.observer/filing/0001828185-25-000018.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828185/000182818525000018/0001828185-25-000018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828185/000182818525000018/brns-20250320.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T10:44:02.316491+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}